Lexeo Therapeutics, Inc. - LXEO
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 8.3% | 6,184,134 | View |
| May 15, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 8.3% | 6,184,134 | View |
| May 15, 2026 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 8.3% | 6,184,134 | View |
| May 15, 2026 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 7.4% | 5,449,272 | View |
| May 15, 2026 | SCHEDULE 13G/A | Balyasny Asset Management L.P. | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | BAM GP LLC | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | Balyasny Asset Management Holdings LP | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | Dames GP LLC | 9.69% | 7,176,144 | View |
| May 15, 2026 | SCHEDULE 13G/A | Dmitry Balyasny | 9.69% | 7,176,144 | View |
| Apr 13, 2026 | SCHEDULE 13G | SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% | 5,674,778 | View |
| Apr 13, 2026 | SCHEDULE 13G | Averill Master Fund, Ltd. | 6.5% | 4,827,730 | View |
| Apr 13, 2026 | SCHEDULE 13G | AARON COWEN | 7.7% | 5,674,778 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Balyasny Asset Management L.P. | 9.89% | 7,221,555 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BAM GP LLC | 9.89% | 7,221,555 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Balyasny Asset Management Holdings LP | 9.89% | 7,221,555 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dames GP LLC | 9.89% | 7,221,555 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dmitry Balyasny | 9.89% | 7,221,555 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Advisors LLC | 7.2% | 5,405,269 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Advisors Holdings LP | 7.2% | 5,405,269 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel GP LLC | 7.2% | 5,405,269 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Securities LLC | 0.0% | 6,600 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Securities Group LP | 0.1% | 92,950 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Citadel Securities GP LLC | 0.1% | 92,950 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Kenneth Griffin | 7.4% | 5,498,219 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 6.5% | 4,763,198 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 6.5% | 4,763,198 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 6.5% | 4,763,198 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 5.8% | 4,207,159 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences Public Fund, L.P. | 5.1% | 3,698,271 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.P. | 5.1% | 3,698,271 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLSP, L.L.C. | 5.1% | 3,698,271 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences X, L.P. | 0.1% | 87,424 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.P. | 0.1% | 87,424 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS X, L.L.C. | 0.1% | 87,424 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XI, L.P. | 0.3% | 232,784 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.P. | 0.3% | 232,784 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XI, L.L.C. | 0.3% | 232,784 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Frazier Life Sciences XII, L.P. | 0.6% | 406,246 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XII, L.P. | 0.6% | 406,246 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | FHMLS XII, L.L.C. | 0.6% | 406,246 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | James N. Topper | 0.1% | 87,424 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Patrick J. Heron | 0.1% | 87,424 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.33% | 3,894,310 | View |
| Jan 29, 2026 | SCHEDULE 13G/A | Affinity Asset Advisors, LLC | 7.1% | 5,217,660 | View |
| Jan 29, 2026 | SCHEDULE 13G/A | Michael Cho | 7.1% | 5,217,660 | View |
| Dec 08, 2025 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 9.99% | 7,291,434 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.